Long-term Morbidity of Testicular Cancer Treatment

Urol Clin North Am. 2015 Aug;42(3):393-408. doi: 10.1016/j.ucl.2015.05.002. Epub 2015 Jun 10.

Abstract

Second malignant neoplasms, cardiovascular disease, neurotoxicity and ototoxicity, pulmonary complications, hypogonadism, and nephrotoxicity are potentially life-threatening long-term complications of testicular cancer and its therapy. This article describes the pathogenesis, risks, and management of these late effects experienced by long-term testicular cancer survivors, who are defined as individuals who are disease free 5 years or more after primary treatment. Testicular cancer survivors should follow applicable national guidelines for cancer screening and management of cardiovascular disease risk factors. In addition, health care providers should capitalize on the time of cancer diagnosis as a teachable moment to introduce and promote lifestyle changes.

Keywords: Cardiovascular disease; Hypogonadism; Long-term morbidity; Nephrotoxicity; Neurotoxicity; Second malignant neoplasms; Survivorship; Testicular cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Drug Monitoring / methods
  • Drug Monitoring / psychology
  • Drug-Related Side Effects and Adverse Reactions* / diagnosis
  • Drug-Related Side Effects and Adverse Reactions* / etiology
  • Humans
  • Hypogonadism / chemically induced
  • Kidney Diseases / chemically induced
  • Life Style
  • Male
  • Neoplasms, Germ Cell and Embryonal* / drug therapy
  • Neoplasms, Germ Cell and Embryonal* / psychology
  • Neoplasms, Second Primary / etiology*
  • Nervous System Diseases / chemically induced*
  • Quality of Life*
  • Risk Assessment
  • Survivors / psychology
  • Survivors / statistics & numerical data
  • Testicular Neoplasms* / drug therapy
  • Testicular Neoplasms* / psychology

Substances

  • Antineoplastic Agents

Supplementary concepts

  • Testicular Germ Cell Tumor